Usted buscó: core study (Inglés - Esloveno)

core
jedro

core:
sredica:

tablet core
jedro tablete

tablet core:
jedro tablet: laktoza monohidrat

a total of 181 patients completed the core phase (24 weeks) of the study.
osnovno fazo v študiji (24 tednov) je zaključilo skupno 181 bolnikov.

the arr for patients who switched from placebo to fingolimod 0.5 mg was 0.22 (0.42 in the core study).
pri bolnikih, ki so prešli z uporabe placeba na odmerek 0,5 mg fingolimoda, je bila pogostnost zagonov, preračunana na eno leto, 0,22 (v osnovni študiji 0,42).

patients who were classified as responders at the end of the 6 month core study were eligible to enter an extended follow-up period.
bolniki, ki so se odzvali na zdravljenje v 6-mesečni osnovni študiji, so veljali za primerne za podaljšano spremljanje.

patients were treated with ranibizumab 0.5 mg pro re nata (prn) in the same eye as the core study (d2301 restore).
bolniki so prejemali ranibizumab 0,5 mg po shemi odmerjanja pro re nata (prn, po potrebi) v isto oko kot v osnovni študiji z oznako d2301 (restore).

between months 12 and 24, the arr for patients on fingolimod 0.5 mg in the core study who remained on 0.5 mg was 0.20 (0.19 in the core study).
med 12. in 24. mesecem je bila pri bolnikih, ki so v glavni študiji prejemali odmerek 0,5 mg fingolimoda in nadaljevali s tem odmerkom, pogostnost zagonov, preračunana na eno leto, 0,20 (v osnovni študiji 0,19).

an extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.
pri otrocih, ki so zaključili enoletno zdravljenje z bodisi zoledronsko kislino ali s pamidronatom v osnovni študiji, so izvedli še 12- mesečno podaljšanje študije, da bi preverili dolgoročno splošno varnost in varnost za ledvice pri odmerjanju zoledronske kisline enkrat ali dvakrat na leto.

19 clinical studies in dementia associated with parkinson’ s disease the efficacy of rivastigmine in dementia associated with parkinson’ s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
klinične študije pri demenci, povezani s parkinsonovo boleznijo učinkovitost rivastigmina pri demenci, povezani s parkinsonovo boleznijo, so pokazali v 24- tedenski multicentrični, dvojno slepi, s placebom kontrolirani osnovni študiji in njeni 24- tedenski odprti podaljšani fazi.